Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing three components: - **Emtricitabine** and **tenofovir disoproxil fumarate** are antiretroviral drugs, both classified as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). They act by inhibiting the activity of HIV-1 reverse transcriptase, thereby blocking viral replication. - **T101 No.2** does not correspond to a known pharmaceutical ingredient in standard drug databases or literature; it may refer to an internal code, formulation identifier, or possibly another active or excipient component not widely recognized. The combination of emtricitabine and tenofovir disoproxil fumarate is commonly used for the treatment and prevention (as pre-exposure prophylaxis) of HIV infection due to their synergistic antiviral effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil fumarate + T101 No.2.